A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer-Reference-Cited by-同舟云学术

A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer

Published:2019-02-28 Issue:25 Volume:38 Page:4977-4989
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Bai Shanshan,Cao Subing,Jin Lianjin,Kobelski Margaret,Schouest Blake,Wang Xiaojie,Ungerleider Nathan,Baddoo Melody,Zhang Wensheng,Corey Eva,Vessella Robert L.,Dong Xuesen,Zhang Kun,Yu Xianghui,Flemington Erik K.,Dong Yan

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Defense

National Natural Science Foundation of China

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences

Richard M Lucas Foundation

U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-019-0768-8.pdf

Reference83 articles.

1. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792–8.

2. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99.

3. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18.

4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity;Proceedings of the National Academy of Sciences;2024-07-25

2. Androgen Signaling in Prostate Cancer: When a Friend Turns Foe;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-05-31

3. Androgen Receptor interacts with c-Myc to regulate macrophage-osteoclast axis and drive bone metastasis in Triple Negative Breast Cancer;2024-05-02

4. Curcumin synergistically augments the chemotherapeutic activity of Doxorubicin in prostate cancer cells;Interdisciplinary Medical Journal;2024-04-29

5. Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer;Journal of Experimental & Clinical Cancer Research;2024-02-27